Drug Profile

Trastuzumab biobetter - United BioPharma

Alternative Names: UB-926

Latest Information Update: 28 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator United BioPharma
Class Antineoplastics; Biobetters; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jun 2022 No recent reports of development identified for preclinical development in Breast-cancer in Taiwan (Parenteral)
15 Oct 2021 Preclinical trials in Breast cancer in China (Parenteral) (United BioPharma pipeline, October 2021)
24 Aug 2018 United BioPharma has patent protection for defucosylation technology to enhance the antibody dependent cellular cytotoxicity (ADCC) activity of anti-cancer antibody drugs (United BioPharma website, August 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com